drugset / Trial / NCT07442006

Glycemic Variability of Combination Therapies in T2DM

NCT07442006

Phase 4 Recruiting 178 enrolled JW Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

Glycemic Variability of Combination Therapies in T2DM

Timeline

Start
2025-10-29
Primary completion
2027-03-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Anagliptin Small molecule 100 mg Oral
Subject Empagliflozin Small molecule 5 mg Oral
Subject Empagliflozin Small molecule 10 mg Oral
Comparator Linagliptin Small molecule 5 mg Oral
Subject Metformin Small molecule 500 mg Oral
Subject Metformin Small molecule 1000 mg Oral